<DOC>
	<DOC>NCT00445185</DOC>
	<brief_summary>The current extension study will assess the persistence of anti-HBs antibodies at Months 12, 24 and 36 after primary vaccination with Henogen's HBV vaccine or Fendrix™. This protocol posting deals with the objectives &amp; outcome measures of the extension phase at Months 12, 24 and 36. The objectives &amp; outcome measures of the primary phase are presented in a separate protocol posting (NCT00291941).</brief_summary>
	<brief_title>Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™</brief_title>
	<detailed_description>Subjects who received complete full vaccination with Henogen HBV adjuvanted vaccine or Fendrix™ will participate in this persistence study for three long-term time points (12, 24 and 36 months after the first dose of primary vaccination). Blood sampling will be done at each time point to measure immune persistence.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Written informed consent obtained from the subject/ from the parent/ guardian of the subject. Subjects who completed the full course of primary vaccination. Immunosuppression caused by the administration of parenteral steroids or chemotherapy. Any confirmed or suspected human immunodeficiency virus (HIV) infection.</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Dialysis</keyword>
	<keyword>Pre-dialysis</keyword>
	<keyword>Hepatitis B vaccine</keyword>
	<keyword>vaccine</keyword>
</DOC>